IL6 and COVID-19: Furthermore, early on during the COVID-19 pandemic, IL-6 inhibition was used as an investigational treatment (42), which disrupts the intestinal barrier (43), and has been associated with a higher incidence of coinfections in COVID-19 patients (44).